Esophageal Neoplasm: Clinical Trials

8 trials for Esophageal Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 2 terminated, 1 active not recruiting, 1 completed. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Unknown 4, Terminated 2, Active not recruiting 1, Completed 1
Phase 11Active not recruiting 1

Follow Esophageal Neoplasm: new trials by email Literature Review of Esophageal Neoplasm trials Research Report on Esophageal Neoplasm

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
Camrelizumab - Esophageal Neoplasm, Immunotherapy
Phase 1 / Phase 2Active not recruitingFujian Medical University Union Hospital252021-11-102025-11-19
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
itraconazole - Esophageal Neoplasm, Esophageal Diseases
Phase 2UnknownHangzhou Cancer Hospital382020-10-012020-10-14
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
Omegaven - Esophageal Neoplasm, Gastric Neoplasm
Phase 2TerminatedUniversity Hospitals, Leicester212012-05-012016-05-26
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
Cetuximab - Esophageal Neoplasm
Phase 2UnknownGabriella Alexandersson von Döbeln512011-01-012018-09-21
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
Docetaxel, Fluorouracil - Esophageal Neoplasm, Chemoradiation
Phase 2UnknownZhu Yujia1202010-10-012016-11-21
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Temozolomide - Colorectal Neoplasm, Head and Neck Neoplasm
Phase 2TerminatedMerck Sharp & Dohme LLC862007-01-262017-06-08
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure) - Esophageal Cancer, Cancer of the Esophagus
Phase 2CompletedUniversity of Alabama at Birmingham252002-01-012023-05-25
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
UFT (Tegafur/Uracil) - Esophageal Neoplasm
Phase 2UnknownEdelman, Martin, M.D.2005-06-24

Narrower conditions

Esophageal Neoplasms (8)  ·  Esophageal Squamous Cell Carcinoma (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Diseases (1)  ·  Head and Neck Neoplasms (1)  ·  Stomach Neoplasms (1)

Broader conditions

Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Gastrointestinal Diseases (8)  ·  Gastrointestinal Neoplasms (8)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Esophageal Diseases (7)  ·  Head and Neck Neoplasms (7)  ·  Carcinoma (2)  ·  Carcinoma, Squamous Cell (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Neoplasms, Squamous Cell (2)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)

Interventions

Docetaxel (2)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Esophagectomy (1)  ·  Fish Oils (1)  ·  Fluorouracil (1)  ·  Irinotecan (1)  ·  Itraconazole (1)  ·  Pharmaceutical Preparations (1)  ·  Radiotherapy (1)  ·  Tegafur (1)  ·  Temozolomide (1)  ·  Uracil (1)  ·  camrelizumab (1)  ·  fish oil triglycerides (1)

Sponsors

Edelman, Martin, M.D. (1)  ·  Fujian Medical University Union Hospital (1)  ·  Gabriella Alexandersson von Döbeln (1)  ·  Hangzhou Cancer Hospital (1)  ·  Merck Sharp & Dohme LLC (1)  ·  University Hospitals, Leicester (1)  ·  University of Alabama at Birmingham (1)  ·  Zhu Yujia (1)

Countries

China (3)  ·  United States (2)  ·  United Kingdom (1)

Top investigators

Chun Chen, Dortor (1)  ·  David J Bowrey, MD (1)  ·  James A. Posey, M.D. (1)  ·  Yonghong Hu, MD (1)

Results publications

PMID 23443801, PMID 27342748, PMID 37700348, PMID 41803866

NIH funding

2008 (1)